Net Loss (USD)

Depreciation and Amortization (USD)

Loss on Disposal of Fixed Assets (USD)

Interest Paid in Kind (USD)

Stock-Based Compensation (USD)

Amortization of Debt Discount (USD)

Loss on Extinguishment of Debt (USD)

Amortization of License Revenue (USD)

Net Cash Used in Operating Activities (USD)

Purchase of Property and Equipment (USD)

Net Cash Used in Investing Activities (USD)

Principal Payments on Notes Payable (USD)

Payment of Debt Refinancing Fees (USD)

Proceeds from Issuance of Note Payable (USD)

Taxes Paid on Vested Restricted Stock Units (USD)

Payments on Finance Lease Obligations (USD)

Payment of Deferred Financing Fees (USD)

Net Cash (Used in) Provided by Financing Activities (USD)

Net (Decrease) Increase in Cash and Cash Equivalents (USD)

Accounts Receivable (USD)

Inventories (USD)

Prepaid Expenses and Other Current Assets (USD)

Deposits and Other Assets (USD)

Accounts Payable (USD)

Accrued Expenses (USD)

Other Current and Non-Current Liabilities (USD)

Cash and Cash Equivalents - Beginning of Period (USD)

Cash and Cash Equivalents - End of Period (USD)

7b961f860b289ffa42896710a96c41e15f68e82ac64447e111675760337eb22e

United States

- International

Total Revenue

e855369f08b6aaf625ca2a644532420508466ec422c1bee9c60e3cc2fe8a6389

ADMA BioManufacturing

- Immunoglobulin Products

- Contract Manufacturing

- Intermediate By-products

Plasma Collection Centers

- Human Plasma Sales

Corporate

0b484bb0df93ad35bb0008dedda53258665ad5b9ba645c625c8aaf5b4289c588

Minimum volume of RSV Plasma sold by PLASMA SUPPLIER per Contract Year (L)

cda8bf33768aa8d2568676b8ecf0afae7e911dc099283fa7c461258194cb11b7

Revenues (USD, thousands)

Cost of product revenue (USD, thousands)

Gross profit (USD, thousands)

Research and development expenses (USD, thousands)

Plasma center operating expenses (USD, thousands)

Amortization of intangible assets (USD, thousands)

Selling, general and administrative expenses (USD, thousands)

Total operating expenses (USD, thousands)

Income from operations (USD, thousands)

Interest income (USD, thousands)

Interest expense (USD, thousands)

Other expense, net (USD, thousands)

Income (loss) before income taxes (USD, thousands)

Provision for income taxes (USD, thousands)

Net income (loss) (USD, thousands)

Basic earnings (loss) per common share (USD)

Diluted earnings (loss) per common share (USD)

204451f8207f4943037da2cff684af8fe1428fda56e0b0157f8cf0f7c2eacc85

Cash and cash equivalents (USD, thousands)

Accounts receivable, net (USD, thousands)

Inventories (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Intangible assets, net (USD, thousands)

Goodwill (USD, thousands)

Right-to-use assets (USD, thousands)

Deposits and other assets (USD, thousands)

TOTAL ASSETS (USD, thousands)

Accounts payable (USD, thousands)

Accrued expenses and other current liabilities (USD, thousands)

Current portion of deferred revenue (USD, thousands)

Current portion of lease obligations (USD, thousands)

Total current liabilities (USD, thousands)

Senior notes payable, net of discount (USD, thousands)

Deferred revenue, net of current portion (USD, thousands)

End of term fee (USD, thousands)

Lease obligations, net of current portion (USD, thousands)

Other non-current liabilities (USD, thousands)

TOTAL LIABILITIES (USD, thousands)

Preferred Stock (USD, thousands)

Common Stock - voting (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

TOTAL STOCKHOLDERS’ EQUITY (USD, thousands)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (USD, thousands)

6e102aea8ef806c393e7c2c2b3fe3d8d357c64490c3d09008e7b216dd6d2595c

ADMA Biologics Inc (ADMA)

Financials